Thiopurines with low-dose allopurinol (ThiLDA)—a prospective clinical one-way crossover trial

[1]  H. Tilg,et al.  3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1 Diagnosis and Medical Management , 2017, Journal of Crohn's & colitis.

[2]  T. Molnár,et al.  Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. , 2017, Journal of Crohn's & colitis.

[3]  C. Parker,et al.  Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. , 2016, The Cochrane database of systematic reviews.

[4]  A. Timmer,et al.  Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. , 2016, The Cochrane database of systematic reviews.

[5]  G. Peters,et al.  The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study. , 2013, Journal of Crohn's & colitis.

[6]  G. Rogler,et al.  Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations , 2013, European Journal of Clinical Pharmacology.

[7]  A. V. van Bodegraven,et al.  Safety and Effectiveness of Long-term Allopurinol–Thiopurine Maintenance Treatment in Inflammatory Bowel Disease , 2013, Inflammatory bowel diseases.

[8]  J. Macdonald,et al.  Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. , 2013, The Cochrane database of systematic reviews.

[9]  S. Vermeire,et al.  Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management , 2012 .

[10]  J. Sanderson,et al.  Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. , 2012, Journal of Crohn's & colitis.

[11]  C. Stedman,et al.  Allopurinol might improve response to azathioprine and 6‐mercaptopurine by correcting an unfavorable metabolite ratio , 2011, Journal of gastroenterology and hepatology.

[12]  P. Higgins,et al.  Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. , 2010, Journal of Crohn's & colitis.

[13]  J. V. van Ginkel,et al.  Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8‐year intercept cohorts , 2010, Inflammatory bowel diseases.

[14]  S. Hanauer,et al.  European evidence-based consensus on the diagnosis and management of Crohn’s disease , 2007, Gut.

[15]  S. Hanauer,et al.  Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  E. Seidman,et al.  Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy. , 2005, Clinical chemistry.

[17]  S. Hanauer,et al.  Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine , 2005, Alimentary pharmacology & therapeutics.

[18]  M. Dubinsky.  Optimizing immunomodulator therapy for inflammatory bowel disease , 2003, Current gastroenterology reports.

[19]  M. Gerig,et al.  A controlled double blind study of azathioprine in the management of Crohn's disease. , 1995, Gut.